



Auro Laboratories Limited

314, T. V. Industrial Estate, S.K. Ahire Marg,
Worli, Mumbai - 400 030. India
Tel. : + 91 22 6663 5456
Fax : +91 22 6663 5460
E-mail : auro@aurolabs.com
Web : www.aurolabs.com

Reg. Off. / Mfg. Unit :
K-56, M. I. D. C. Tarapur,
Dist. Palghar, Maharashtra - 401506.
CIN No. L33125MH1989PLC051910

Date: May 30, 2025

To,
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001.

Scrip Code/ ISIN: 530233/ INE292C01011

Sub: Outcome of the meeting of Board of Directors dated May 30, 2025.

Dear Sir / Madam,

Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at their Meeting to be held on (i.e. **Friday, May 30, 2025**), inter alia, considered the following matters:

1. Approved the appointment of Mr. Kuntal Pancholi, as the Chief Financial Officer and Key Managerial Personnel of the Company on the recommendation of Nomination and Remuneration Committee and based on approval of the Audit Committee of the Company w.e.f. May 30, 2025.

Details as required under Regulation 30 of the of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 ("Master Circular") is attached herewith as **Annexure - A.**

2. Approved the appointment of M/s. Pokharna and Associates, Chartered Accountants (FRN: 151048W), as the Internal Auditors of the Company on the recommendation of the Audit Committee for the F.Y. 2025-2026.

Details as required under Regulation 30 of the of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 ("Master Circular") is attached herewith as **Annexure - B.**

3. Approved the Audited Financial Results of the Company for the quarter and year ended March 31, 2025, as recommended by the Audit Committee.





Auro Laboratories Limited

314, T. V. Industrial Estate, S.K. Ahire Marg,
Worli, Mumbai - 400 030. India
Tel. : + 91 22 6663 5456
Fax : +91 22 6663 5460
E-mail : auro@aurolabs.com
Web : www.aurolabs.com

Reg. Off. / Mfg. Unit :
K-56, M. I. D. C. Tarapur,
Dist. Palghar, Maharashtra - 401506.
CIN No. L33125MH1989PLC051910

Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, we are enclosing herewith the following:

- Audited Financial Results for the quarter and year ended March 31, 2025 along with the Statement of Assets and Liabilities and Cash Flow Statement of the Company as on the date.
- Auditor Report on the Financial Results received from the Statutory Auditors of the Company for the Quarter and year ended March 31, 2025.
- Declaration regarding the Auditor's report with unmodified opinion on the Audited Financial Results of the Company for the financial year ended on March 31, 2025.

The Meeting of the Board of Directors commenced at 5 p.m. and concluded at 6 p.m.

The results along with the QR code will be published in the newspapers in terms of Regulation 47(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in due course.

Kindly take the above on record.

Thanking You,

Yours Faithfully,

For **AURO LABORATORIES LIMITED**

SIDDHARTHA DEORAH
WHOLE TIME DIRECTOR
DIN: 00230796



Encl.: A/a



Annexure-A

Details as required under Regulation 30 of the of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 ("Master Circular") for the appointment of Chief Financial Officer.

Reason for Change viz, appointment	Appointment as Chief Financial Officer and Key Managerial Personnel of the Company.
Date of Appointment and Term of Appointment	Appointment from May 30, 2025. Mr. Kuntal Pancholi is appointed as Chief Financial Officer and Key Managerial Personnel of the Company as per the provisions of the applicable laws.
Brief Profile	More than 29 years of experience in Accounts and Finance Department. Education : Graduate from Mumbai University.
Disclosures of Relationships between directors (in case of appointment of director)	Not Applicable





Auro Laboratories Limited

314, T. V. Industrial Estate, S.K. Ahire Marg,
Worli, Mumbai - 400 030. India
Tel. : + 91 22 6663 5456
Fax : +91 22 6663 5460
E-mail : auro@aurolabs.com
Web : www.aurolabs.com

Reg. Off. / Mfg. Unit :
K-56, M. I. D. C. Tarapur,
Dist. Palghar, Maharashtra - 401506.
CIN No. L33125MH1989PLC051910

Annexure-B

Details as required under Regulation 30 of the of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 ("Master Circular") for the appointment of Internal Auditor.

Reason for Change viz, appointment	Appointment
Date of Appointment and Term of Appointment	Appointment from May 30, 2025. The appointment of M/s. Pokharna and Associates, Chartered Accountants, (FRN: 151048W) as the Internal Auditors of the Company shall be for a period of 1 (one) year, with effect from April 01, 2025 till March 31, 2026.
Brief Profile	Practicing CA since last 12 years Expertise in direct and Indirect taxes Handling Clients Pan India
Disclosures of Relationships between directors (in case of appointment of director)	Not Applicable



AURO LABORATORIES LIMITED

CIN NO. :- L33125MH1989PLC051910

Regd. Office : K - 56 M.I.D.C INDUSTRIAL AREA, TARAPUR

DIST. PALGHAR 401506, MAHARASHTRA

Tel.: +91-22-66635456 Email: auro@aurolabs.com Web: www.aurolabs.com

ANNEXURE - I**PART-1: STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2025**

Part - I		(Rs. In Lakhs except EPS)				
Sr. No.	Particulars	Quarter Ended			Year Ended	
		31-03-2025	31-12-2024	31-03-2024	31-03-2025	31-03-2024
		(Ref. Note 4)	(Unaudited)	(Ref. Note 4)	(Audited)	(Audited)
1	Revenue from Operations	740.00	305.47	1,206.29	1,939.84	5,363.52
2	Other Income	12.94	14.09	39.85	65.60	150.39
3	Total Income (1 + 2)	752.94	319.56	1,246.14	2,005.44	5,513.91
4	Expenses					
	a. Cost of raw material consumed	334.27	118.02	576.48	506.29	2,903.70
	b. Purchase of Stock-in-trade	-	-	-	1.64	-
	c. Changes in inventories of finished goods, work-in-progress and stock in trade	179.30	110.38	(136.51)	412.75	(247.98)
	d. Employee benefits expense	63.80	3.40	213.33	246.71	514.38
	e. Finance Cost	30.44	24.57	(32.49)	108.24	73.57
	f. Depreciation and amortisation expenses	28.62	27.00	28.24	109.62	109.24
	g. Other Expenses	81.25	29.37	312.01	432.12	1,126.43
	Total Expenses (4)	717.69	312.75	961.06	1,817.35	4,479.34
5	Profit / (Loss) before exceptional items and tax (3 ± 4)	35.25	6.81	285.08	188.09	1,034.57
6	Exceptional items					
7	Profit / (Loss) before tax (5 ± 6)	35.25	6.81	285.08	188.09	1,034.57
8	Tax expense					
	(a) Current tax expenses for current year	1.93	1.71	71.75	10.31	274.08
	(b) MAT credit (where applicable)					
	(c) Deferred tax	(6.10)	-	(18.73)	(6.10)	(18.73)
9	Profit / (Loss) for the period from continuing operation (7 ± 8)	39.42	5.10	232.05	183.88	779.21
10	Profit / (Loss) for discontinuing operations	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-
12	Profit / (Loss) for discontinuing operation (after tax) (10 ± 11)	-	-	-	-	-
13	Profit / (Loss) for the period (after tax) (9 ± 12)	39.42	5.10	232.05	183.88	779.21
14	Other Comprehensive Income					
	A. Items that will not be reclassified subsequently to profit or loss					
	(i) Items that will not be reclassified to profit or loss	15.53	5.05	42.94	15.53	42.94
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(3.91)	(1.27)	(10.81)	(3.91)	(10.81)
	B. Items that will be reclassified subsequently to profit or loss					
	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total other comprehensive income /(loss), net of tax (14)	11.62	3.78	32.13	11.62	32.13
15	Total Comprehensive Income for the period [comprising Profit/(Loss) for the period (after tax) and other comprehensive income (after tax)] (13 ± 14)	51.04	8.88	264.19	195.50	811.34
16	Paid-up equity share capital (Face value of Rs. 10 each)	623.25	623.25	623.25	623.25	623.25
17	Other Equity				3,673.56	3,572.60
18	Earnings per share (EPS) (Face Value - Rs. 10 per Equity Shares)					
	(a) Basic	0.63	0.08	3.72	2.95	12.50
	(b) Diluted	0.63	0.08	3.72	2.95	12.50

Notes on financial results:-

- The above audited financial results for the quarter and year ended March 31, 2025 were reviewed by the Audit Committee and thereafter approved by the Board of Directors at meeting held on May 30, 2025.
- The Company operates in single segment i.e. "Pharmaceuticals", and hence does not have any additional disclosures to be made under Ind As 108 on operating Segments.
- The above audited results, published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 have been prepared in accordance with Indian Accounting Standards (IND AS) notified under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015; Companies (Indian Accounting Standards) (Amendment) Rules, 2016 and guidelines issued by the Security and Exchange Board of India (SEBI) and other accounting principles generally accepted in India.
- Figures for the Quarter ended on 31st March, 2025 & 31st March, 2024 are the balancing figures between audited results in respect of the full financial year and the published year to the date upto the third quarter of the respective financial year
- Figures for the previous period have been regrouped/reclassified wherever necessary to confirm to current period's classifications.
- Pursuant to Master Circular No. SEBI/HO/DDHS/PoD1/P/CIR/2023/119 dated 10 August 2021 issued by the SEBI with respect to the SEBI (Issue and Listing of Non-Convertible Securities) Regulations, 2021 the Company is not a Large Corporate as per the applicability criteria given under the Chapter XII of the aforeside circular.

FOR & BEHALF OF BOARD OF DIRECTORS

AURO LABORATORIES LIMITED

SIDDHARTHA DEORAH
WHOLE TIME DIRECTOR
DIN: 00230796

Place : Mumbai
Date : 30/05/2025

AURO LABORATORIES LIMITED

CIN NO. :- L33125MH1989PLC051910

Regd. Office : K - 56 M.I.D.C INDUSTRIAL AREA, TARAPUR

DIST. PALGHAR 401506 , MAHARASHTRA

Tel.: +91-22-66635456 Email. auro@aurolabs.com Web: www.aurolabs.com

Part II- Statement of Assets and Liabilities (Ind AS)

(Rs. In Lakh)

Particulars	As at 31.03.2025	As at 31.03.2024
	Audited	Audited
A ASSETS		
1. Non-Current Assets		
(a) Property, Plant and Equipment	2,105.84	2,215.03
(b) Capital Work -in-Progress	5,647.52	3,268.07
(c) Investment Property	-	-
(d) Financial Assets		
(i) Investments	4.88	4.88
(ii) Loans	-	-
(iii) Others	-	-
(e) Other non-current assets	-	-
2. Current assets		
(c) Inventories	366.79	823.97
(b) Financial Assets		
(i) Investments	-	-
(ii) Trade Reveivables	939.34	1,339.23
(iii) Cash and cash equivalents	0.03	99.22
(iv) Bank balances other than (iii) above	62.93	65.67
(v) Loans	-	-
(vi) Others- To be specified	782.28	757.25
(c) Other Current Assets	-	-
TOTAL ASSETS	9909.61	8,573.31
B EQUITY AND LIABILITIES		
1. Equity		
(a) Equity Share Capital	623.25	623.25
(b) Other Equity	3,673.56	3,572.60
2. Liabilities		
(I) Non-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	3,308.53	1,837.82
(ii) Trade payables	-	-
(iii) Other Financial Liabilities	-	-
(b) Provisions	-	-
(c) Deferred Tax Liabilities (Net)	140.11	146.21
(d) Other Non-Current Liabilities	-	-
(II) Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	1,192.90	786.57
(ii) Trade Payables		
(A) Total outstanding dues of micro enterprises and small enterprises		
(B) total outstanding dues of creditors other than micro enterprises and small enterprises	621.34	620.49
(b) Other Current Liabilities	339.61	698.74
(c) Provisions	10.31	287.65
(d) Current Tax Liabilities (net)	-	-
TOTAL EQUITY AND LIABILITIES	9909.61	8,573.31

FOR & BEHALF OF BOARD OF DIRECTORS

AURO LABORATORIES LIMITED

SIDDHARTHA DEORAH
WHOLE TIME DIRECTOR
DIN: 00230796

Place : Mumbai
Date : 30/05/2025

AURO LABORATORIES LIMITED

CIN NO. :- L33125MH1989PLC051910

Regd. Office : K - 56 M.I.D.C INDUSTRIAL AREA, TARAPUR

DIST. PALGHAR 401506 , MAHARASHTRA

Tel.: +91-22-66635456 Email. auro@aurolabs.com Web: www.aurolabs.com

Part III- Cash Flow Statement

(Amount in Rs.Lakh)

Particulars	For the year ended 31.03.2025		For the year ended 31.03.2024	
A. Cash flow from operating activities				
Net Profit / (Loss) before extraordinary items and tax		188.09		1,034.57
Add: Adjustments for:				
Depreciation and amortisation	109.62		109.24	
Other Non Cash Items	(20.51)		32.13	
Finance costs	108.24		73.57	
		197.35		214.94
		385.44		1,249.51
Less: Adjustment for:				
Interest income	7.15		6.65	-
Dividend income	-		-	-
		7.15		-
Operating profit / (loss) before working capital changes		378.29		1,242.86
Changes in working capital:				
Adjustments for (increase) / decrease in operating assets:				
Inventories	457.18		351.61	
Trade receivables	399.89		(98.76)	
Loans and advances	(25.03)		151.22	
Long-term loans and advances				
Other non-current assets	-		-	
		832.04		404.07
		1,210.33		1,646.92
Adjustments for increase / (decrease) in operating liabilities:				
Trade payables	0.85		(527.54)	
Other current liabilities	(359.13)		579.75	
Other long-term liabilities				
Short-term provisions	(277.34)		181.58	
Long-term provisions	-		-	
		(635.62)		233.80
		574.71		1,880.72
Cash flow from extraordinary items		-		-
Cash generated from operations		574.71		1,880.72
Net income tax (paid) / refunds				
Net cash flow from / (used in) operating activities (A)		574.71		1,880.72
B. Cash flow from investing activities				
Capital expenditure on fixed assets, including capital advance	(2,380.08)		(3,564.02)	
Proceeds from sale of fixed assets	0.20			
Interest received				
- Others	7.15		6.65	
Dividend received				
- Others	-		-	
		(2,372.73)		(3,557.37)
Net income tax (paid) / refunds		(72.71)		(309.64)
Net cash flow from / (used in) investing activities (B)		(2,445.44)		(3,867.02)
C. Cash flow from financing activities				
Proceeds from long-term borrowings	1,470.71		1,661.97	
Repayment of borrowings & Net increase / (decrease) in working capital borrowings	-		-	
Proceeds from other short-term borrowings	-		354.15	
Repayment of other short-term borrowings	406.33		(7.59)	
Finance cost	-		(25.50)	
	(108.24)		(73.57)	
		1,768.81		1,909.462
Cash flow from extraordinary items		-		-
Net cash flow from / (used in) financing activities (C)		1,768.81		1,909.48
Net increase/(decrease) in Cash & cash equivalents (A+B+C)		(101.92)		(76.82)
Cash and cash equivalents at the beginning of the year		164.88		241.70
Cash and cash equivalents at the end of the year		62.96		164.88

FOR & BEHALF OF BOARD OF DIRECTORS

AURO LABORATORIES LIMITED

SIDDHARTHA DEORAH

WHOLE TIME DIRECTOR

DIN: 00230796

Place : Mumbai

Date : 30/05/2025



Kothari Jain & Associates

Chartered Accountants

Mob.: 9637777007

001, Shubham Heritage, Behind Gopal Building, Ambadi Road, Vasai Road (West), Palghar - 401 202.
Email : kothari_jain@hotmail.com

Date :

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF THE STANDALONE FINANCIAL RESULTS OF THE COMPANY

To the Board of Directors of Auro Laboratories Limited

1. We have audited the accompanying Standalone Financial Results of Auro Laboratories Limited ("the Company"), for the quarter and year ended 31st March 2025 ('the Standalone Statement'), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
 - a. is presented in accordance with the requirements of Regulation 33 and Regulation 52 of the Listing Regulations, in this regard; and
 - b. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards and other accounting principles generally accepted in India, of the net profit for the quarter and year ended 31st March 2025, other comprehensive income, and other financial information of the Company for the quarter and year ended 31st March 2025.

Basis of opinion

3. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial Standalone Statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the Standalone Statement.

Management's and Those Charged with Governance Responsibilities for the Statement

4. This Standalone Statement has been prepared based on the audited Standalone Financial Statements for the year ended March 31, 2025.



The Company's Management and the Board of Directors are responsible for the preparation of these Standalone Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

5. In preparing the Standalone Financial Results, the Management and the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Statement

6. Our objectives are to obtain reasonable assurance about whether the Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken based on these Financial Results.
7. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.
 - Obtain an understanding of internal control relevant to the audit to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial Standalone Statements on whether the entity has adequate internal financial controls with reference to financial Standalone Statements in place and the operating effectiveness of such controls.



- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.
 - Conclude on the appropriateness of the Management and the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Standalone Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern; and
 - Evaluate the overall presentation, structure, and content of the Financial Results, including the disclosures, and whether the Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
8. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
 9. We also provide those charged with governance with a Standalone Statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

10. Attention is drawn to the fact that the figures for the quarter ended 31st March 2025 and the corresponding quarter ended in the previous year as reported in these standalone financial results are the balancing figures between audited figures in respect of full financial year and the published year to date unaudited figures up to the end of the third quarter of the relevant financial year which were subjected to limited review by us. Our opinion is not modified in respect of this matter.

For Kothari Jain & Associates.

Chartered Accountants
(Firm Reg. No. 113041W)

(Sunil Kumar Kothari)
Proprietor
Membership No. 043842
UDIN: 25043842BMJKBW2415
Place: Mumbai
Date: 30/05/2025





Auro Laboratories Limited

314, T.V. Industrial Estate, S.K. Ahire Marg,
Worli, Mumbai - 400 030. India
Tel. : + 91 22 6663 5456
Fax : +91 22 6663 5460
E-mail : auro@aurolabs.com
Web : www.aurolabs.com

Reg. Off. / Mfg. Unit :
K-56, M. I. D. C. Tarapur,
Dist. Palghar, Maharashtra - 401506.
CIN No. L33125MH1989PLC051910

Date: May 30, 2025

To
BSE Limited,
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Reg: Security Code No. 530233

Sub: Declaration pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir / Ma'am,

Pursuant to the provision of Regulation 33(3)(d) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 as amended by SEBI Notification No. SEBI / LAD-NRO / GN / 2016-17 / 001 dated May 25, 2016 read with SEBI Circular No. CIR / CFD / CMD / 56 / 2016 dated May 27, 2016, we hereby declared that the Statutory Auditors of the Company M/s. Kothari Jain & Associates, Chartered Accountants, Mumbai (Firm Registration No. 113041W) have issued the Audit Reports with an Unmodified Opinion in respect of the Audited Financial Results for the quarter & year ended on March 31, 2025.

Kindly take the same on your record and acknowledge.

Thanking you,

For AURO LABORATORIES LIMITED

Siddhartha Deorah

**SIDDHARTHA DEORAH
WHOLE TIME DIRECTOR
(DIN: 00230796)**

